Coherus Oncology (CHRS) Short term Debt (2016 - 2025)
Historic Short term Debt for Coherus Oncology (CHRS) over the last 9 years, with Q1 2025 value amounting to $26.2 million.
- Coherus Oncology's Short term Debt changed N/A to $26.2 million in Q1 2025 from the same period last year, while for Mar 2025 it was $26.2 million, marking a year-over-year change of. This contributed to the annual value of $13.6 million for FY2024, which is 31272.73% up from last year.
- Coherus Oncology's Short term Debt amounted to $26.2 million in Q1 2025.
- In the past 5 years, Coherus Oncology's Short term Debt ranged from a high of $26.2 million in Q1 2025 and a low of $90000.0 during Q2 2023
- For the 4-year period, Coherus Oncology's Short term Debt averaged around $9.5 million, with its median value being $9.2 million (2024).
- Over the last 5 years, Coherus Oncology's Short term Debt had its largest YoY gain of 1012444.44% in 2024, and its largest YoY loss of 12777.23% in 2024.
- Coherus Oncology's Short term Debt (Quarter) stood at $17.3 million in 2021, then crashed by 80.93% to $3.3 million in 2023, then soared by 312.73% to $13.6 million in 2024, then soared by 92.57% to $26.2 million in 2025.
- Its last three reported values are $26.2 million in Q1 2025, $13.6 million for Q4 2024, and $9.2 million during Q3 2024.